Clinical Trials Directory

Trials / Completed

CompletedNCT03368547

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
400 (actual)
Sponsor
Jonsson Comprehensive Cancer Center · Academic / Other
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery. Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread.

Detailed description

PRIMARY OBJECTIVE: I. To assess the sensitivity and specificity of gallium Ga 68 gozetotide (68Ga-PSMA-11) PET for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis, and on a per patient basis using nodal regional correlation. SECONDARY OBJECTIVES: I. To assess the positive and negative predictive value of 68Ga-PSMA-11 PET for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis, and on a per patient basis using nodal regional correlation. II. To assess sensitivity, specificity, positive and negative predictive value of 68Ga- PSMA-11 PET for the detection of extra-pelvic nodal metastases, visceral metastases and osseous metastases compared to biopsy and imaging follow-up. OUTLINE: Patients receive 68Ga-PSMA-11 intravenously (IV) and undergo PET/CT scan over 20-50 minutes on day 1. After completion of study, patients are followed up at 2-4 days, then at 12 months.

Conditions

Interventions

TypeNameDescription
PROCEDUREComputed TomographyUndergo PET/CT scan
RADIATIONGallium Ga 68 GozetotideGiven IV
PROCEDUREPositron Emission TomographyUndergo PET/CT scan

Timeline

Start date
2016-12-12
Primary completion
2021-06-18
Completion
2021-06-18
First posted
2017-12-11
Last updated
2023-04-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03368547. Inclusion in this directory is not an endorsement.